JP2016504993A5 - - Google Patents

Download PDF

Info

Publication number
JP2016504993A5
JP2016504993A5 JP2015548649A JP2015548649A JP2016504993A5 JP 2016504993 A5 JP2016504993 A5 JP 2016504993A5 JP 2015548649 A JP2015548649 A JP 2015548649A JP 2015548649 A JP2015548649 A JP 2015548649A JP 2016504993 A5 JP2016504993 A5 JP 2016504993A5
Authority
JP
Japan
Prior art keywords
seq
protein
immunogenic composition
cdtb
isolated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015548649A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016504993A (ja
JP6515036B2 (ja
Filing date
Publication date
Priority claimed from GBGB1223342.5A external-priority patent/GB201223342D0/en
Application filed filed Critical
Publication of JP2016504993A publication Critical patent/JP2016504993A/ja
Publication of JP2016504993A5 publication Critical patent/JP2016504993A5/ja
Application granted granted Critical
Publication of JP6515036B2 publication Critical patent/JP6515036B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015548649A 2012-12-23 2013-12-20 C.ディフィシルCDTb及び/又はCDTaタンパク質のエレメントを含む免疫原性組成物 Expired - Fee Related JP6515036B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1223342.5A GB201223342D0 (en) 2012-12-23 2012-12-23 Immunogenic composition
GB1223342.5 2012-12-23
PCT/EP2013/077762 WO2014096393A1 (en) 2012-12-23 2013-12-20 Immunogenic composition comprising elements of c. difficile cdtb and/or cdta proteins

Publications (3)

Publication Number Publication Date
JP2016504993A JP2016504993A (ja) 2016-02-18
JP2016504993A5 true JP2016504993A5 (enExample) 2017-02-02
JP6515036B2 JP6515036B2 (ja) 2019-05-15

Family

ID=47682553

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015548649A Expired - Fee Related JP6515036B2 (ja) 2012-12-23 2013-12-20 C.ディフィシルCDTb及び/又はCDTaタンパク質のエレメントを含む免疫原性組成物

Country Status (12)

Country Link
US (2) US9669083B2 (enExample)
EP (1) EP2934579B1 (enExample)
JP (1) JP6515036B2 (enExample)
CN (1) CN105120892B (enExample)
AR (1) AR094275A1 (enExample)
AU (1) AU2013366450A1 (enExample)
BR (1) BR112015014727B8 (enExample)
CA (1) CA2894951C (enExample)
ES (1) ES2748054T3 (enExample)
GB (1) GB201223342D0 (enExample)
SG (1) SG11201504701UA (enExample)
WO (1) WO2014096393A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT201700124T1 (it) 2010-09-03 2017-05-08 Valneva Austria Gmbh Polipeptide isolato delle proteine di tossina a e tossina b di c. difficile e relativi usi
ES2969952T3 (es) 2011-04-22 2024-05-23 Wyeth Llc Composiciones relacionadas con una toxina mutante de Clostridium difficile y sus procedimientos
EP2788022B1 (en) * 2011-12-08 2018-10-31 GlaxoSmithKline Biologicals SA Clostridium difficile toxin-based vaccine
BR122016023101B1 (pt) * 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
JP6688233B2 (ja) * 2014-06-25 2020-04-28 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム クロストリジウム・ディフィシル免疫原性組成物
SG11201908376UA (en) * 2017-03-15 2019-10-30 Novavax Inc Methods and compositions for inducing immune responses against clostridium difficile
US10933126B2 (en) 2018-05-03 2021-03-02 The Board Of Regents Of The University Of Oklahoma Clostridium difficile immunogenic compositions and methods of use
CA3102353A1 (en) 2018-06-19 2019-12-26 Glaxosmithkline Biologicals Sa Immunogenic composition
CN111793130B (zh) * 2019-03-20 2021-09-14 华中农业大学 一株副猪嗜血杆菌CdtB杂交瘤细胞及单克隆抗体应用
EP4003256B1 (en) 2019-07-30 2025-12-10 The Government of The United States, as Represented by The Secretary of The Army Layered composite for scar treatment and prevention
WO2021255690A2 (en) 2020-06-19 2021-12-23 Pfizer Inc. Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof
GB202205833D0 (en) 2022-04-21 2022-06-08 Glaxosmithkline Biologicals Sa Bacteriophage
WO2025029561A2 (en) * 2023-07-28 2025-02-06 University Of South Florida Vaccine containing rbd2 of cdtb component from binary toxin cdt of clostridioides difficile

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX348670B (es) * 2009-02-11 2017-06-23 Cedars Sinai Medical Center Anticuerpo contra toxina de distensión citoletal de campylobacter jejuni.
US10046040B2 (en) 2009-11-16 2018-08-14 University Of Maryland, Baltimore Multivalent live vector vaccine against Clostridium difficile-associated disease
SMT201700124T1 (it) * 2010-09-03 2017-05-08 Valneva Austria Gmbh Polipeptide isolato delle proteine di tossina a e tossina b di c. difficile e relativi usi
AR089797A1 (es) * 2012-01-27 2014-09-17 Merck Sharp & Dohme Vacunas contra clostridum difficile que comprenden toxinas recombinantes

Similar Documents

Publication Publication Date Title
JP6048845B2 (ja) ジフテリア毒素の無毒性突然変異体crm197又はその断片を含む融合タンパク質
JP7094103B2 (ja) インフルエンザウイルスワクチンおよびその使用
JP6735269B2 (ja) インフルエンザウイルスワクチンおよびその使用
JP2015500827A5 (enExample)
WO2018109220A3 (en) Novel recombinant prefusion rsv f proteins and uses thereof
PH12012500849A1 (en) Mycobacterial vaccines
JP2013520487A5 (enExample)
JP2016510983A5 (enExample)
JP2014530010A5 (enExample)
JP2014502253A5 (enExample)
JP2015529677A5 (enExample)
CN115175696A (zh) 包含白喉毒素交叉反应物质(crm)氨基酸序列的蛋白颗粒及其用途
RU2014127714A (ru) ВАКЦИНА НА ОСНОВЕ ТОКСИНОВ Clostridium difficile
Metz et al. Nanoparticle delivery of a tetravalent E protein subunit vaccine induces balanced, type-specific neutralizing antibodies to each dengue virus serotype
CA2901888C (en) Influenza nucleoprotein vaccines
JP2023123432A (ja) ワクチン及びコンジュゲートワクチンプラットフォームとしての改変されたクロストリジウム神経毒
HRP20170094T1 (hr) Imunogeni pripravak
RU2015106916A (ru) Полипептиды clostridium difficile в виде вакцины
JP2009520758A5 (enExample)
McComb et al. Neutralizing antibody and functional mapping of Bacillus anthracis protective antigen—The first step toward a rationally designed anthrax vaccine
JP2016520534A5 (enExample)
Liu et al. Immunological characterisation and immunoprotective efficacy of functional domain antigens of botulinum neurotoxin serotype A
Song et al. A rationally designed form of the TLR5 agonist, flagellin, supports superior immunogenicity of Influenza B globular head vaccines
JP5661744B2 (ja) 腸球菌由来のポリペプチド、及びワクチン接種のためのその使用
Sam et al. Synthetic particulate subunit vaccines for the prevention of Q fever